ISK received the FDA’s approval to start Phase 1b/2a with AML patients
January 9, 2020Related Posts
-
Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors
February 17, 2022The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.
-
PHASE 1B/2A Clinical trial started
April 13, 2021 -
Cooperation with Harvard Medical School (MGH)
October 27, 2019ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
